NCT05452668 2024-08-21
Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients
Children's Cancer Hospital Egypt 57357
Phase NA Unknown
Clinical Trials
1,016 trialsNCT04298892 2024-07-01
INTHEMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Unknown
NCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
NCT05899751 2024-05-10
Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate
BTG International Inc.
Unknown
NCT06224452 2024-03-05
Is Ibrutinib-related Atrial Fibrillation Dose Dependent
University Hospital, Caen
Unknown
NCT06293586 2024-03-05
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Cairo University
Phase NA Unknown
NCT06285136 2024-02-29
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
The Second Affiliated Hospital of Kunming Medical University
Phase 2/3 Unknown
NCT04330820 2024-02-28
RELAX
Technische Universität Dresden
Phase 1/2 Unknown
NCT06279585 2024-02-28
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
University of Seville
Phase NA Unknown
NCT06277011 2024-02-26
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
NCT02192619 2024-02-23
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Unknown
NCT05865678 2024-02-21
SKETCh
The Christie NHS Foundation Trust
Unknown
NCT04021368 2024-02-14
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA
Phase 1 Unknown
NCT06258629 2024-02-14
Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality
Sohag University
Unknown
NCT06224309 2024-02-09
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Unknown
NCT04582487 2024-02-07
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Unknown
NCT04731974 2024-02-07
Acute Concussion and Melatonin
Children's National Research Institute
Phase 2 Unknown
NCT06246006 2024-02-07
MPL - NPM
Centre Hospitalier Universitaire de NÄ«mes
Unknown
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT06238336 2024-02-02
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
Shanxi Bethune Hospital
Phase 2/3 Unknown
NCT04358393 2024-02-01
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06234904 2024-01-31
Study of IBR733 Cell Injection in Acute Myeloid Leukemia
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1 Unknown
NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT04284228 2024-01-16
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
NexImmune Inc.
Phase 1/2 Unknown
NCT04776005 2024-01-03
COVIDVAC OH
Assistance Publique - Hôpitaux de Paris
Unknown
NCT06177561 2023-12-20
Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT
Ruijin Hospital
Phase NA Unknown
NCT03236129 2023-12-18
DLI-Boost
Assistance Publique - Hôpitaux de Paris
Phase 3 Unknown
NCT05846672 2023-12-12
Turkish Cultural Adaptation, Validity and Reliability of the "Gait Outcomes Assessment List"
Istanbul University - Cerrahpasa
Unknown
NCT05692713 2023-12-08
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
University of British Columbia
Unknown
NCT06162325 2023-12-08
Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients
Peking Union Medical College Hospital
Unknown
NCT06160115 2023-12-07
The Role of NK Cells to Detect Blood Infection in ALL.
Assiut University
Unknown
NCT04599556 2023-12-06
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
Zhejiang University
Phase 1 Unknown
NCT04372524 2023-12-05
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
University of British Columbia
Unknown
NCT05925660 2023-12-05
MUCOPS
Universitaire Ziekenhuizen KU Leuven
Phase NA Unknown
NCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT03614858 2023-11-29
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT03896854 2023-11-29
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT04257175 2023-11-28
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression
Sheba Medical Center
Phase 2/3 Unknown
NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT05025150 2023-11-28
Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial
Sutter Health
Unknown
NCT05583175 2023-11-28
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05803395 2023-11-28
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT05235633 2023-11-24
ADLs at the End of Acute Treatment for Childhood Leukemia and Non-Hodgkin Lymphoma
Technical University of Munich
Unknown
NCT05918198 2023-11-21
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Peking University People's Hospital
Phase 2 Unknown
NCT06141304 2023-11-21
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Phase 2 Unknown
NCT06134297 2023-11-18
Adherence, Viability, Clinical Evolution and Therapeutic Efficacy in Patients Undergoing Bone Marrow Transplantation
Federal University of Health Science of Porto Alegre
Phase NA Unknown
NCT06130709 2023-11-14
IRAF-ABLATION Study: a Multicenter International Retrospective Cohort of Patients With BTK Inhibitors-related AF Treated by Catheter Ablation
University Hospital, Caen
Unknown
NCT06125106 2023-11-09
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Zhejiang University
Phase 1 Unknown
NCT06121765 2023-11-08
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
Assiut University
Unknown
NCT06087419 2023-11-02
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown